Apimeds Pharmaceuticals US (APUS) vs CNS Pharmaceuticals (CNSP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Apimeds Pharmaceuticals US is the larger company by market cap ($8.3 million vs $7.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | APUS | CNSP |
|---|---|---|
| Share price | $5.51 | $5.35 |
| Market cap | $8.32M | $7.82M |
| 1-day change | -21.84% | -1.47% |
| YTD return | -66.40% | — |
| 1-year return | -70.53% | — |
| EPS (TTM) | $-36.03 | $-17.90 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $59.70 | $10.54 |
| 52-week low | $1.51 | $1.90 |
| Distance from 52-week high | -90.77% | -49.24% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +86.92% |
| Average volume | 3.66M | 6.40K |
| Shares outstanding | 1.51M | 1.46M |
| Employees | — | 8 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Apimeds Pharmaceuticals US
APUS stock →Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure.
Healthcare · Drug Manufacturers - Specialty & Generic
About CNS Pharmaceuticals
CNSP stock →CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors.
Healthcare · Biotechnology · 8 employees
APUS vs CNSP FAQ
Which is bigger, Apimeds Pharmaceuticals US or CNS Pharmaceuticals?
Apimeds Pharmaceuticals US (APUS) is larger, with a market capitalization of $8.32M compared with $7.82M for CNS Pharmaceuticals (CNSP).
Are Apimeds Pharmaceuticals US and CNS Pharmaceuticals in the same industry?
Both are in the Healthcare sector, but in different industries: Drug Manufacturers - Specialty & Generic for Apimeds Pharmaceuticals US and Biotechnology for CNS Pharmaceuticals.